Document:

<PAGE>

                                                                    EXHIBIT 10.3

                                                                  Execution Copy

                           CONFIDENTIALITY AGREEMENT,

                           DATED AS OF APRIL 8, 2002,

                                 BY AND BETWEEN

                            ICN PHARMACEUTICALS, INC.

                                       AND

                                 RIBAPHARM INC.

<PAGE>

                            CONFIDENTIALITY AGREEMENT

This CONFIDENTIALITY AGREEMENT is made and entered into as of April 8, 2002, by
and between ICN Pharmaceuticals, Inc., a Delaware corporation ("ICN"), and
Ribapharm Inc., a Delaware corporation and a wholly owned subsidiary of ICN
("Ribapharm").

                                    RECITALS

          WHEREAS, the Board of Directors of ICN has determined that it would be
in the best interests of ICN and its stockholders to separate certain assets and
businesses from ICN;

          WHEREAS, ICN has caused Ribapharm to be incorporated in order to
effect such separation;

          WHEREAS, ICN has, pursuant to resolutions of its Board of Directors
adopted on August 7, 2000, contributed to Ribapharm, certain assets, including
its nucleoside analog library and subject to certain consents, the Exclusive
License and Supply Agreement between ICN and Schering-Plough Ltd. dated July 28,
1995, as amended;

          WHEREAS, Ribapharm has previously filed the IPO Registration Statement
(as herein defined) with the Securities and Exchange Commission but it has not
yet become effective; and

          WHEREAS, ICN and Ribapharm desire to enter into this Agreement
concerning the obligations of the parties with respect to confidential or
proprietary information, intellectual property, and other matters that are set
forth below.

          NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements herein contained, and for
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, and intending to be legally bound hereby, the parties
hereby agree as follows:

DEFINITIONS:

          For all purposes of this Agreement, and except as otherwise expressly
provided, capitalized terms used herein shall have the following meanings:

          "AFFILIATE" means a Ribapharm Affiliate or an ICN Affiliate, as the
case may be.

          "BUSINESS DAY" means any day other than a Saturday, a Sunday, or a day
on which banking institutions located in the State of California are authorized
or obligated by law or executive order to close.

          "CONFIDENTIAL INFORMATION" means Ribapharm Confidential Information or
ICN Confidential Information, as the case may be.

                                       -2-

<PAGE>

          "CONTRIBUTION DATE" means August 7, 2000.

          "CONTROL" means the possession, direct or indirect, of the power to
direct or cause the direction of the management of the policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.

          "CONTROLLED" has the meaning correlative to the definition of
"CONTROL."

          "COPYRIGHTS" means all registered and unregistered copyrights and
applications therefor.

          "DISPUTES" has the meaning ascribed thereto in Section 3.1.

          "ICN" has the meaning ascribed in the preamble hereto.

          "ICN AFFILIATE" means a Person that, directly or indirectly through
one or more intermediaries, is Controlled by ICN (other than Ribapharm and any
Subsidiary of Ribapharm).

          "ICN BUSINESSES" means the businesses conducted by ICN and/or any ICN
Affiliate at any time on or before the Contribution Date, but excluding the
Ribapharm Business.

          "ICN CONFIDENTIAL INFORMATION" means confidential or proprietary
information relating to the ICN Businesses, including, but not limited to, any
unpublished Technology, unpublished patent applications, and other confidential
or proprietary technical and business information relating to the ICN
Businesses.

          "IPO REGISTRATION STATEMENT" means the Registration Statement on Form
S-1, Registration No. 333-39350, of Ribapharm, as supplemented and amended from
time to time.

          "PATENTS" means all patents and patent applications (including any
divisions, continuations, continuations-in-part, reexaminations, extensions,
renewals or reissues thereof), design registrations, utility models and similar
rights and applications therefor.

          "PERSON" means an individual, partnership, limited liability company,
joint venture, corporation, trust, unincorporated association, any other entity,
or any government or any department or agency or other unit thereof.

          "RIBAPHARM" has the meaning ascribed in the preamble hereto.

          "RIBAPHARM AFFILIATE" means a Person that, directly or indirectly
through one or more intermediaries, is Controlled by, or is under common Control
with Ribapharm (other than any ICN Affiliate).

                                       -3-

<PAGE>

          "RIBAPHARM BUSINESS" means the business associated with the assets
contributed to Ribapharm by ICN by resolution of ICN's board of directors,
including, but not limited to, (i) all information and research and development
relating to all of the chemical compounds included among the assets contributed
to Ribapharm by ICN, (ii) all business operations whose financial performance is
reflected in the financial statements (including the notes thereto) for the
period ended December 31, 2000, as set forth in the Registration Statement on
Form S-1, Reg. No. 333-39350, as it may be amended (the "Ribapharm Financial
Statements") and (iii) all related business operations initiated by Ribapharm
after the date of the Ribapharm Financial Statements.

          "RIBAPHARM CONFIDENTIAL INFORMATION" means confidential or proprietary
information relating exclusively to the Ribapharm Business, including, but not
limited to, any unpublished Technology, unpublished patent applications, and
other confidential or proprietary technical and business information relating
exclusively to the Ribapharm Business.

          "SERVICE AGENT" means (i) for ICN, The Corporation Trust Company, with
offices on the date hereof at 1209 Orange Street, Wilmington, County of New
Castle, Delaware 19801; and (ii) for Ribapharm, The Corporation Trust Company,
with offices on the date hereof at 1209 Orange Street, Wilmington, County of New
Castle, Delaware 19801.

          "SUBSIDIARY" means with respect to any specified Person, any
corporation or other legal entity of which such Person or any of its
Subsidiaries Controls or owns, directly or indirectly, more than 50% of the
stock or other equity interest entitled to vote with respect to the election of
members to the board of directors or similar governing body; provided, however,
that for the purposes of this Agreement, neither Ribapharm nor any of the
Subsidiaries of Ribapharm shall be deemed to be Subsidiaries of ICN or of any of
the Subsidiaries of ICN.

          "TECHNOLOGY" means all technology and know-how, including, without
limitation, technical information, trade secrets and knowledge, design rights
(other than statutory registrations), whether included in or derived from
specifications, manuals, notebooks, reports, documents, blue prints, inventions,
drawings, formulae, procedures, processes, devices, software and source code and
documentation therefor, flow charts, recording media, and other intangible,
tangible and electronic embodiments of information.

1.        CONFIDENTIALITY

          1.1   ICN agrees to keep confidential and not disclose, and shall
cause each ICN Affiliate to keep confidential and not disclose, to any third
party and not to use for any purpose not authorized by Ribapharm, in whole or in
part, any Ribapharm Confidential Information.

          1.2   Ribapharm agrees to keep confidential and not disclose, and to
cause each Ribapharm Affiliate to keep confidential and not disclose, to any
third party and not to use for any purpose not authorized by ICN, in whole or in
part, any ICN Confidential Information.

                                       -4-

<PAGE>

          1.3   For purposes of this Agreement, ICN Confidential Information and
Ribapharm Confidential Information do not include, and a party and a party's
Affiliates (a party and Affiliates of the party being referred to as the
"receiving party") will have no obligations under this Agreement, with respect
to any information of the other party or any Affiliate of the other party (the
other party and Affiliates of the other party being referred to as the
"disclosing party") which:

          (i)   in the case of ICN, is known to ICN from a source other than the
Ribapharm Business or Ribapharm, as evidenced by competent proof thereof; or

          (ii)  in the case of Ribapharm, is known to Ribapharm from a source
other than the ICN Businesses, as evidenced by competent proof thereof; or

          (iii) is or becomes publicly known through no wrongful act of the
receiving party (in which event the receiving party's obligations under this
Agreement in respect thereto shall terminate on the date such information enters
the public domain); or

          (iv)  is or was rightfully received by the receiving party from a
third party without violation of any obligations of confidentiality and/or use
restrictions owed by the third party to the disclosing party or any other party;
or

          (v)   is independently developed by employees or consultants of the
receiving party without use of or reference to the disclosing party's
proprietary information; or

          (vi)  is approved for release by the prior written authorization of
the disclosing party.

          In addition, if the receiving party is requested or required (by oral
questions, interrogatories, request for information or documents, subpoena,
civil investigative demand, similar process or otherwise) to disclose any
Confidential Information of the disclosing party, such receiving party will
provide prompt notice to the disclosing party on such request(s) so that such
disclosing party may seek any appropriate protective order and/or waive
compliance with the provisions of this Agreement. Failing the entry of a
protective order or the receipt of a waiver hereunder, if the receiving party is
in the opinion of its attorneys legally required to disclose any of the
disclosing party's Confidential Information under pain of liability for contempt
or other material censure or material penalty, the receiving party may disclose
such Confidential Information without liability hereunder upon notice to the
disclosing party. Notwithstanding the foregoing, ICN is permitted to disclose
Ribapharm Confidential Information as required in litigation that is pending as
of the Contribution Date, but shall use its reasonable best efforts to obtain
confidential treatment of any such information disclosed.

2.        COOPERATION

          2.1   The parties will do everything that is necessary or appropriate
to conform to the purpose and spirit of this Agreement, including, without
limitation, cooperating with the other party in connection with the maintenance,
enforcement and protection of the Copyrights, Patents

                                       -5-

<PAGE>

and Technology, and executing any and all documents or instruments, or obtaining
any consents, in order to assign, transfer, perfect, record, maintain, enforce
or otherwise carry out the intent of the terms of this Agreement.

          2.2   Each party will take appropriate measures to assure the
confidentiality and non-use obligations and other applicable obligations of a
party pursuant to this Agreement are met by its legal representatives, members
of supervisory bodies, management, employees or other agents.

3.        MISCELLANEOUS

          3.1   AUTHORITY. Each of the parties hereto represents and warrants to
the other that (a) it has the corporate power and authority to execute, deliver
and perform this Agreement, (b) the execution, delivery and performance of this
Agreement by it has been duly authorized by all necessary corporate action, (c)
it has duly and validly executed and delivered this Agreement, and (d) this
Agreement is a legal, valid and binding obligation, enforceable against it in
accordance with its terms subject to applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting creditors' rights
generally and general equity principles. The representations and warranties
contained in this Section 3.2 shall survive the execution and delivery hereof
until the expiration of all applicable statutes of limitations.

          3.2   COMPLETE AGREEMENT. This Agreement constitutes the entire
agreement between the parties hereto with respect to the subject matter hereof
and shall supersede all prior agreements and understandings, whether written or
oral, between the parties with respect to such subject matter.

          3.3   GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of California (without giving effect to
the conflict of laws principals thereof) as to all matters, including matters of
validity, construction, effect, performance and remedies.

          3.4   NOTICES. All notices and other communications hereunder shall be
in writing and shall be delivered in person, by telecopy, by express or
overnight mail delivered by a nationally recognized air courier (delivery
charges prepaid), or by registered or certified mail (postage prepaid, return
receipt requested) to the respective parties as follows:

          (a)   If to ICN, to:

                ICN Pharmaceuticals, Inc.
                3300 Hyland Avenue
                Costa Mesa, CA  92626
                Attention:  Gregory Keever, Esq.

                                       -6-

<PAGE>

          (b)   If to Ribapharm, to:

                Ribapharm Inc.
                3300 Hyland Avenue
                Costa Mesa, CA  92626
                Attention:  Roger D. Loomis, Esq.

or to such other address as the party to whom notice is given may have
previously furnished to the others in writing in the manner set forth above. Any
notice or communication delivered in person shall be deemed effective on
delivery or when delivery is refused. Any notice or communication sent by
telecopy or by air courier shall be deemed effective on the first Business Day
at the place at which such notice or communication is received following the day
on which such notice or communication was sent.

          3.6   AMENDMENT AND MODIFICATION. This Agreement may not be amended or
modified in any respect except by a written agreement signed by both of the
parties hereto.

          3.7   BINDING EFFECT; ASSIGNMENT. This Agreement and all of the
provisions hereof shall be binding upon the parties hereto and inure to the
benefit of the parties hereto and their respective successors and permitted
assigns. Except with respect to a merger of either party with another Person,
neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assigned by either party hereto without the prior written consent of
the other party.

          3.8   THIRD PARTY BENEFICIARIES. Nothing in this Agreement, express or
implied, is intended to or shall confer upon any Person any legal or equitable
right, benefit or remedy of any nature whatsoever under or by reason of this
Agreement, and no Person (other than as provided in the previous sentence) shall
be deemed a third party beneficiary under or by reason of this Agreement.

          3.9   COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. The Agreement may be
executed by facsimile signature.

          3.10  WAIVER. The observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or
prospectively) by the party entitled to enforce such term, but such waiver shall
be effective only if it is in writing signed by the party against which such
waiver is to be asserted. Unless otherwise expressly provided in this Agreement,
no delay or omission on the part of any party in exercising any right or
privilege under this Agreement shall operate as a waiver thereof, nor shall any
waiver on the part of any party of any right or privilege under this Agreement
operate as a waiver of any other right or privilege under this Agreement nor
shall any single or partial exercise of any right or privilege preclude any
other or further exercise thereof or the exercise of any other right or
privilege under this Agreement. No failure by either party to take any action or
assert any right or privilege

                                       -7-

<PAGE>

hereunder shall be deemed to be a waiver of such right or privilege in the event
of the continuation or repetition of the circumstances giving rise to such right
unless expressly waived in writing by the party against whom the existence of
such waiver is asserted.

          3.11  SEVERABILITY. Any provision of this Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof. Any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.

          3.12  REMEDIES. Each of ICN and Ribapharm shall be entitled to enforce
its rights under this Agreement specifically, to recover damages and costs
(including reasonable attorneys' fees) caused by any breach of any provision of
this Agreement and to exercise all other rights existing in its favor. Each of
ICN and Ribapharm acknowledges and agrees that under certain circumstances the
breach by ICN or any of its Affiliates or Ribapharm or any of its Affiliates of
a term or provision of this Agreement will materially and irreparably harm the
other party, that money damages will accordingly not be an adequate remedy for
such breach and that the non-defaulting party, in its sole discretion and in
addition to its rights under this Agreement and any other remedies it may have
at law or in equity, may apply to any court of law or equity of competent
jurisdiction (without posting any bond or deposit) for specific performance
and/or other injunctive relief in order to enforce or prevent any breach of the
provisions of this Agreement.

          3.13  PERFORMANCE. Each of the parties hereto shall use all
commercially reasonable efforts to cause to be performed all actions, agreements
and obligations set forth herein to be performed by any Affiliate of such party.

          3.14  REFERENCES; CONSTRUCTION. The section and other headings and
subheadings contained in this Agreement are solely for the purpose of reference,
are not part of the agreement of the parties hereto, and shall not in any way
affect the meaning or interpretation of this Agreement. All references to days
or months shall be deemed references to calendar days or months. Unless the
context otherwise requires, any reference to a "Section" shall be deemed to
refer to a section of this Agreement. The words "hereof," "herein" and
"hereunder" and words of similar import referring to this Agreement refer to
this Agreement as a whole and not to any particular provision of this Agreement.
Whenever the words "include," or "including" are used in this Agreement, unless
otherwise specifically provided, they shall be deemed to be followed by the
words "without limitation." This Agreement shall be construed without regard to
any presumption or rule requiring construction or interpretation against the
party drafting or causing the document to be drafted.

                                       -8-

<PAGE>

          3.15  EFFECTIVENESS. This Agreement shall become effective upon the
time of purchase of the Firm Shares, as defined in the Underwriting Agreement,
by and among ICN, Ribapharm and the underwriters named therein relating to the
initial public offering by Ribapharm.

                                 * * * * * * * *

                                       -9-

<PAGE>

          IN WITNESS WHEREOF, each of the parties has caused this Agreement to
be executed on its behalf by its officers thereunto duly authorized on the day
and year first above written.

                                              Ribapharm Inc.

                                              By:    ---------------------------
                                              Name:
                                              Title:

                                              ICN Pharmaceuticals, Inc.

                                              By:    ---------------------------
                                              Name:
                                              Title:

                                      -10-<PAGE>

                                                                    EXHIBIT 10.4

                                                                  EXECUTION COPY

                              TAX SHARING AGREEMENT

                                       BY

                            ICN PHARMACEUTICALS, INC.

                                       AND

                                 RIBAPHARM INC.

<PAGE>

                                TABLE OF CONTENTS

                                                                            PAGE

SECTION 1.        Definition of Terms                                        2

SECTION 2.        Allocation of Income Tax Liabilities                       8

SECTION 3.        Preparation and Filing of Tax Returns                     13

SECTION 4.        Refunds, Carrybacks and Tax Benefits                      16

SECTION 5.        Tax Payments and Intercompany Billings                    21

SECTION 6.        Assistance and Cooperation                                26

SECTION 7.        Tax Records                                               27

SECTION 8.        Tax Contests                                              28

SECTION 9.        No Inconsistent Actions                                   29

SECTION 10.       Survival of Obligations                                   33

SECTION 11.       Employee Matters                                          33

SECTION 12.       Treatment of Payments; Tax Gross Up                       33

SECTION 13.       Disagreements                                             34

SECTION 14.       Late Payments                                             35

SECTION 15.       Expenses                                                  35

SECTION 16.       General                                                   35

<PAGE>

                                                                  EXECUTION COPY

                              TAX SHARING AGREEMENT

        This Agreement is entered into as of April 8, 2002, by ICN
Pharmaceuticals, Inc., a Delaware corporation ("ICN"), and Ribapharm Inc., a
Delaware corporation ("Ribapharm"). Capitalized terms used in this Agreement are
defined herein. Unless otherwise indicated, all "Section" references in this
Agreement are to sections of this Agreement.

                                    RECITALS

        WHEREAS, the board of directors of ICN has determined that it would be
in the best interests of ICN and its stockholders to completely separate the
Biotechnology Business from ICN;

        WHEREAS, ICN has caused Ribapharm to be incorporated in order to effect
such separation; WHEREAS, ICN has contributed and transferred to Ribapharm, and
Ribapharm has received, all the assets associated with the Biotechnology
Business;

        WHEREAS, ICN and Ribapharm intend that the contribution of the assets
associated with the Biotechnology Business qualified as a tax-free transfer
under Section 351 or 368(a)(1)(D) of the Code;

        WHEREAS, ICN currently owns all of the issued and outstanding Ribapharm
common stock; WHEREAS, ICN and Ribapharm currently contemplate that ICN will
make an initial public offering of an amount of ICN's Ribapharm common stock
that will reduce ICN's ownership of stock in Ribapharm to not less than 80% of
the combined voting power and value of all outstanding Ribapharm stock;

        WHEREAS, ICN currently contemplates that, following such initial public
offering, and subject to the satisfaction of certain conditions, ICN will
distribute to the holders of its common stock on a pro rata basis all of the
shares of Ribapharm common stock then owned by ICN;

<PAGE>

        WHEREAS, ICN and Ribapharm intend that the Distribution will be tax-free
to ICN and its stockholders under Section 355 and related provisions of the
Code;

        WHEREAS, as a result of the Distribution, Ribapharm will cease to be a
member of the affiliated group of which ICN is the common parent, effective as
of the Distribution Date; and

        WHEREAS, ICN and Ribapharm desire to provide for and agree upon the
allocation between the parties of liabilities for Taxes arising prior to, as a
result of, and subsequent to the Distribution, and to provide for and agree upon
other matters relating to Taxes;

        NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements herein contained, and for
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, and intending to be legally bound hereby, the parties
hereby agree as follows:

SECTION 1.      Definition of Terms.

For purposes of this Agreement (including the recitals hereof), the following
terms have the following meanings:

          "Accounting Cutoff Date" means, with respect to Ribapharm, any date as
of the end of which there is a closing of its financial accounting records.

          "Adjustment Request" means any formal or informal claim or request
filed with any Tax Authority, or with any administrative agency or court, for
the adjustment, refund, or credit of Taxes, including (a) any amended Tax Return
claiming adjustment to the Taxes as reported on the Tax Return, or if
applicable, as previously adjusted, or (b) any claim for refund or credit of
Taxes previously paid.

          "Affiliate" means any entity that directly or indirectly is
"controlled" by the person or entity in question. "Control" means the
possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a person, whether through ownership
of

                                        2

<PAGE>

voting securities, by contract or otherwise. Except as otherwise provided
herein, the term Affiliate shall refer to Affiliates of a person as determined
immediately after the Distribution.

          "Affiliation and Distribution Agreement" means the Affiliation and
Distribution Agreement between ICN and Ribapharm dated April 8, 2002.

          "Agreement" means this Tax Sharing Agreement.

          "Application for Ruling" means the letter, including all exhibits and
appendices attached thereto, filed by ICN on March 12, 2002, requesting a
private letter ruling from the Internal Revenue Service regarding the tax
consequences of the Distribution, as supplemented and amended from time to time.

          "Biotechnology Business" means the biotechnology business conducted by
Ribapharm that previously was conducted as a division of ICN.

          "Carryback" or "Carryforward" means any net operating loss, net
capital loss, excess tax credit, foreign tax credit or other similar Tax Item
which may or must be carried from one Tax Period to another Tax Period under the
Code or other applicable Tax Law.

          "Code" means the U.S. Internal Revenue Code of 1986, as amended from
time to time, or any successor law.

          "Company" means ICN or Ribapharm, as the context requires.

          "Consolidated Income Tax Return" or "Combined Income Tax Return"
means, for any Consolidated Period, any Tax Return relating to Income Tax which
is computed by reference to the assets and activities of members of the ICN
Group (other than members of the Ribapharm Group) and the Ribapharm Group.

          "Consolidated Period" or "Consolidated Periods" means any taxable
period or periods (or portions thereof) between the Initial Public Offering Date
and the Distribution Date, during which period Ribapharm is a member of the ICN
Group.

          "Contribution" has the meaning set forth in the Affiliation and
Distribution Agreement.

                                        3

<PAGE>

          "Contribution Date" means the date or dates, as the case may be, of
the Contribution.

          "Distribution" means the distribution after the Initial Public
Offering by ICN of all of ICN's shares of Ribapharm common stock to ICN
stockholders.

          "Distribution Date" means the date on which the Distribution occurs.

          "Distribution Date Straddle Period" means any Tax Period that begins
before the Distribution Date and ends after the Distribuiton Date.

          "Federal Income Tax" means any Income Tax imposed by the United States
government.

          "Foreign Income Tax" means any Income Tax imposed by any foreign
country or any possession of the United States, or by any political subdivision
of any foreign country or United States possession, which is an income tax as
defined in Treasury Regulation Section 1.901-2.

          "Group" means the ICN Group or the Ribapharm Group, as the context
requires.

          "ICN Affiliate" has the meaning set forth in the Affiliation and
Distribution Agreement.

          "ICN Federal Consolidated Return" means, for any Consolidated Period,
any United States federal Consolidated Income Tax Return for the affiliated
group (as that term is defined in Code Section 1504) that includes ICN as the
common parent and that includes the Ribapharm Group.

          "ICN Group" means all corporations included in the ICN Federal
Consolidated Return. "Income Tax" means all Taxes (i) based upon, measured by,
or calculated with respect to, net income or net receipts, proceeds or profits
or (ii) based upon, measured by, or calculated with respect to multiple bases
(including, but not limited to, corporate franchise and occupation Taxes) if
such Tax may be based upon, measured by, or calculated with respect to one or
more bases described in clause (i) above.

          "Initial Public Offering" has the meaning set forth in the Affiliation
and Distribution Agreement.

                                        4

<PAGE>

          "Initial Public Offering Date" means the date on which this Agreement
becomes effective pursuant to Section 16.10 of this Agreement.

          "Internal Revenue Service" or "IRS" means the United States Internal
Revenue Service or the United States Department of the Treasury, as the context
requires.

          "IPO Date Straddle Period" means any Tax Period that begins before the
Initial Public Offering Date and ends after the Initial Public Offering Date.

          "IRS Private Letter Ruling" means a private letter ruling issued by
the IRS in response to the Application for Ruling that provides that the
Distribution will qualify under Section 355 and related provisions of the Code
as a tax-free spin-off, and that no income, gain or loss will be recognized for
U.S. federal income tax purposes by ICN, the stockholders or former stockholders
of ICN, or any ICN Affiliate with respect to the Distribution.

          "Other Tax" means any Tax that is not an Income Tax.

          "Payment Date" means (i) with respect to any ICN Federal Consolidated
Return, the due date for any required installment of estimated taxes determined
under Code Section 6655, the due date (determined without regard to extensions)
for filing the return determined under Code Section 6072, and the date the
return is filed, and (ii) with respect to any Consolidated or Combined Income
Tax Return (other than an ICN Federal Consolidated Return), the corresponding
dates determined under the applicable Tax Law.

          "Post-Distribution Period" means any Tax Period that begins on or
after the Distribution Date, and, in the case of any Distribution Date Straddle
Period, the portion of such Distribution Date Straddle Period that begins after
the Distribution Date.

          "Pre-Distribution Period" means any Tax Period that (i) begins on or
after the Initial Public Offering Date and, in the case of any IPO Date Straddle
Peirod, the portion of such IPO Date Straddle Period that begins on or after the
Initial Public Offering Date, and (ii) ends before

                                        5

<PAGE>

the Distribution Date, and, in the case of any Distribution Date Straddle
Period, the portion of such Distribution Date Straddle Period that ends on the
Distribution Date.

          "Prime Rate" means the base rate on corporate loans charged by
Citibank, N.A., New York, New York from time to time, compounded on each March
31, June 30, September 30 and December 31.

          "Responsible Company" means, with respect to any Tax Return, the
Company having responsibility for preparing and filing such Tax Return under
this Agreement.

          "Restructuring Tax" means the Taxes described in clauses (ii) and
(iii) of Section 2.5(a).

          "Ribapharm Group" means Ribapharm and all corporations included in the
Ribapharm Federal Consolidated Return, or, during any Consolidated Period, that
would be included in such Return if Ribapharm was not included in the ICN
Federal Consolidated Return.

          "Ribapharm Federal Consolidated Return" means any United States
federal Income Tax Return or Returns in respect of periods after the
Consolidated Period filed by Ribapharm alone or for the affiliated group (as
that term is defined in Code Section 1504) that includes Ribapharm as the common
parent.

          "Separate Company Tax" means any Tax computed by reference solely to
the assets and activities of a member or members of a single Group.

          "Straddle Period" means any IPO Date Straddle Period or Distribution
Date Straddle Period, as the context requires.

          "State Income Tax" means any Income Tax imposed by any State of the
United States or by any political subdivision of any such State.

          "Tainting Act" shall have the meaning provided in Section 9.

          "Tax" or "Taxes" means any income, gross income, gross receipts,
profits, capital stock, franchise, withholding, payroll, social security,
workers compensation, unemployment, disability, property, ad valorem, stamp,
excise, severance, occupation, service, sales, use, license, lease,

                                        6

<PAGE>

transfer, import, export, value added, alternative minimum, estimated or other
similar tax (including any fee, assessment, or other charge in the nature of or
in lieu of any tax) imposed by any governmental entity or political subdivision
thereof, and any interest, penalties, additions to tax, or additional amounts in
respect of the foregoing.

          "Tax Authority" means, with respect to any Tax, the governmental
entity or political subdivision thereof that imposes such Tax, and the agency
(if any) charged with the collection of such Tax for such entity or political
subdivision.

          "Tax Benefit" means any refund of, credit against, or other reduction
in otherwise required Tax payments (including any reduction in estimated tax
payments) and any interest in respect of the foregoing, net of the effect on
otherwise required Tax payments of any associated or corresponding item of
income or gain, or other increase in otherwise required Tax payments.

          "Tax Contest" means an audit, review, examination, or any other
administrative or judicial proceeding with the purpose or effect of
redetermining Taxes of any of the Companies or their Affiliates (including any
administrative or judicial review of any claim for refund).

          "Tax Item" means, with respect to any Income Tax, any item of income,
gain, loss, deduction, or credit or other item that has the effect of increasing
or decreasing the amount of any Income Tax payable.

          "Tax Law" means the law of any governmental entity or political
subdivision thereof relating to any Tax.

          "Tax Opinion" means a favorable opinion from ICN's counsel regarding
the federal income tax consequences, under Section 355 and related provisions of
the Code, of the Distribution.

          "Tax Opinion Submission" means any and all information, including any
representation or material fact, submitted to counsel in connection with the Tax
Opinion.

                                        7

<PAGE>

          "Tax Period" means, with respect to any Tax, the period for which the
Tax is reported as provided under the Code or other applicable Tax Law.

          "Tax Records" means Tax Returns, Tax Return workpapers, documentation
relating to any Tax Contest, and any other books of account or records required
to be maintained under the Code or other applicable Tax Laws or under any record
retention agreement with any Tax Authority.

          "Tax Return" means any report of Taxes due (including any report of
estimated tax payments), any claims for refund of Taxes paid, any information
return with respect to Taxes, or any other similar report, statement,
declaration, or document required to be filed under the Code or other Tax Law,
including any attachments, exhibits, or other materials submitted with any of
the foregoing, and including any amendments or supplements to any of the
foregoing.

          "Transactions" means the transactions contemplated by the Affiliation
and Distribution Agreement, including the Contribution, the Initial Public
Offering and the Distribution.

          "Treasury Regulations" means the regulations promulgated from time to
time under the Code as in effect for the relevant Tax Period.

SECTION 2.      Allocation of Income Tax Liabilities.

        2.1.    General Rule.

                (a)     ICN Liability. ICN shall indemnify and hold harmless the
Ribapharm Group from and against any liability for Taxes for which ICN is liable
under this Section 2.

                (b)     Ribapharm Liability. Ribapharm shall indemnify and hold
harmless the ICN Group other than members of the Ribapharm Group from and
against any liability for Taxes for which Ribapharm is liable under this Section
2.

                                        8

<PAGE>

                (c)     Except as otherwise provided in the Agreement, this
Agreement allocates liabilities for Taxes between the ICN Group and the
Ribapharm Group solely for Pre-Distribution Periods and Post-Distribution
Periods.

        2.2     Federal Income Tax. Except as otherwise provided in this
Agreement, Federal Income Tax liability shall be allocated as follows:

                (a)     Consolidated Period. For each Consolidated Period,
Ribapharm shall be liable for and pay to ICN an amount equal to the Federal
Income Tax determined under the "Stand Alone Method." Under this method
Ribapharm's liability for Tax for any Taxable Period is computed as if Ribapharm
had (i) never been part of the ICN Group and (ii) filed a consolidated Federal
Income Tax Return as parent of the Ribapharm Group with each eligible member of
that Group; provided, however, that the provisions of Section 2.6(a) regarding
special rules for application of the Stand Alone Method shall apply. ICN shall
be liable for all Federal Income Tax for the Consolidated Period other than
amounts for which Ribapharm is liable pursuant to this Section 2.2(a).

                (b)     Post-Distribution Periods. With respect to all
Post-Distribution Periods, Ribapharm shall be responsible for all Federal Income
Tax imposed on members of the Ribapharm Group, and ICN shall be responsible for
all Federal Income Tax imposed on members of the ICN Group.

        2.3.    State and Foreign Income Taxes. Except as otherwise provided in
this Agreement, State and Foreign Income Tax liability shall be allocated as
follows:

                (a)     State and Foreign Consolidated or Combined Income Taxes.
For each Consolidated Period, Ribapharm shall be liable for and pay to ICN any
State Income Tax or Foreign Income Tax with respect to any Consolidated or
Combined Income Tax Return relating to State Income Tax or Foreign Income Tax in
an amount that is equal to the amount determined under the Stand Alone Method
for the period covered by such Tax Return; provided, however,

                                        9

<PAGE>

that Ribapharm's State Income Tax liability shall be calculated taking into
account ICN's worldwide apportionment schedule, where applicable. ICN shall be
liable for and pay any State Income Tax or Foreign Income Tax with respect to
any Consolidated or Combined Income Tax Return relating to State Income Tax or
Foreign Income Tax other than the amount for which Ribapharm is liable pursuant
to this Section 2.3(a).

                (b)     Separate Company Taxes. For each Pre-Distribution
Period, in the case of any State or Foreign Income Tax which is a Separate
Company Tax, Ribapharm shall be liable for and shall pay any such Separate
Company Tax imposed under Tax Law on any member of the Ribapharm Group and ICN
shall be liable for and shall pay any such Separate Company Tax imposed on any
member of the ICN Group other than a member of the Ribapharm Group.

        2.4     Other Taxes. For each Pre-Distribution Period, except as
otherwise provided in this Agreement, Ribapharm shall be liable to and pay the
applicable Tax Authority any Other Tax that is imposed on any member of the
Ribapharm Group and ICN shall be liable to and pay the applicable Tax Authority
any Other Tax that is imposed on any member of the ICN Group other than a member
of the Ribapharm Group.

        2.5.    Transaction Taxes.

                (a)     General. Except as otherwise provided in this Section
2.5, ICN shall be responsible for and pay, and shall indemnify and hold harmless
the Ribapharm Group from and against any liability for, any and all Taxes
resulting from the Transactions. This shall include but not be limited to (i)
any sales and use, gross receipts, or other transfer Taxes imposed on the
transfers occurring pursuant to the Transactions; (ii) any Tax resulting from
any income or gain recognized under Treasury Regulation Sections 1.1502-13 or
1.1502-19 (or any corresponding provisions of other applicable Tax Laws) as a
result of the Transactions; and (iii), except as otherwise provided in Section
2.5(b), any Tax resulting from any income or gain recognized as a result of any
of the Transactions failing to qualify for tax-free treatment under Code
Sections 351,

                                       10

<PAGE>

355, 361, 368 or other provisions of the Code (as contemplated in the IRS
Private Letter Ruling or the Tax Opinion) or corresponding provisions of other
applicable Tax Laws.

                (b)     Inconsistent Acts and Events. Notwithstanding the
provisions of Section 2.5(a), Ribapharm shall be liable for, and shall indemnify
and hold harmless ICN from and against any liability for, any Restructuring Tax
to the extent arising from (i) any breach by Ribapharm of the representations or
covenants under Section 9, (ii) any Tainting Act performed by Ribapharm, (iii)
the inaccuracy of any factual statements or representations made by Ribapharm to
the IRS in connection with the Application for Ruling, or an IRS Private Letter
Ruling (if issued), and to counsel in connection with any Tax Opinion Submission
(if made) or Tax Opinion (if obtained), but only to the extent such inaccuracy
arises from facts in existence prior to the Distribution Date or (iv) any
Section 355(e) Event with respect to Ribapharm. A Section 355(e) Event with
respect to Ribapharm will occur if Section 355(e) of the Code applies to the
Distribution as a result of one or more persons acquiring directly or indirectly
stock of Ribapharm representing a 50% or greater interest in Ribapharm within
the meaning of Section 355(e).

        2.6.    Calculation of Tax Liability.

                (a)     Stand Alone Method. The following rules shall apply for
purposes of computing Ribapharm's liability under the Stand Alone Method: (i)
transactions during any Consolidated Period between a member of the Ribapharm
Group and a member of the ICN Group that is not a member of the Ribapharm Group
shall, for Federal Income Tax purposes, be accounted for pursuant to the
provisions of the regulations under IRC Section 1502 that govern intercompany
transactions (and to the extent appropriate for State or Foreign Income Tax
purposes, similar rules shall apply in the case of transactions between such
members which are included in State or Foreign Consolidated or Combined Income
Tax Returns); (ii) during Consolidated Periods all computations shall be made in
conformity with the positions, elections and accounting methods used by ICN in
preparing the consolidated returns of the ICN Group; (iii)

                                       11

<PAGE>

the highest marginal tax rate to which the Ribapharm Group could be subject
under applicable Tax Law shall be deemed to be the only Tax rate to which such
group is subject under such law; and (iv) subject to (i) through (iii) above,
all computations and other determinations shall be made in accordance with the
the laws and regulations applying to affiliated groups filing consolidated
returns (including, in the case of any company that becomes or ceases to be a
member of any Group, the laws and regulations applicable to a company that
becomes or ceases to be a member of a such Group), as well as all other relevant
federal Tax laws and regulations (and similar rules shall apply in the case of
State or Foreign Taxes in respect to Consolidated or Combined Returns for such
Taxes).

                (b)     The principles of Treasury Regulation Section
1.1502-76(b) as reasonably interpreted, agreed and applied by the Companies
shall apply in determining whether a Tax Item is attributable to a Tax Period
provided that (x) no election shall be made under Treasury Regulation Section
1.1502-76(b)(2)(ii) (relating to ratable allocation of a year's items) and (y)
if the Distribution Date is not an Accounting Cutoff Date, the provisions of
Treasury Regulation Section 1.1502-76(b)(2)(iii) will be applied to ratably
allocate the items (other than extraordinary items) for the month which includes
the Distribution Date.

                (c)     In determining the apportionment of Tax Items between
Pre-Distribution Periods and Post-Distribution Periods, any Tax Items relating
to the Transactions shall be treated as an extraordinary item described in
Treasury Regulation Section 1.1502-76(b)(2)(ii)(C) and shall be allocated to
Pre-Distribution Periods, and any Taxes related to such items shall be treated
under Treasury Regulation Section 1.1502-76(b)(2)(iv) as relating to such
extraordinary item and shall be allocated to Pre-Distribution Periods.

        2.7.    Tax Payments and Intercompany Billings. Each Company shall pay
the Taxes allocated to it by this Section 2 either to the applicable Taxing
Authority or to the other Company in accordance with Section 5.

                                       12

<PAGE>

SECTION 3.      PREPARATION AND FILING OF TAX RETURNS.

        3.1.    General. Except as otherwise provided in this Section 3, Tax
Returns shall be prepared and filed when due (including extensions) by the
person obligated to file such Tax Returns under the Code or applicable Tax Law.
The Companies shall provide, and shall cause their Affiliates to provide,
assistance and shall cooperate with one another in accordance with Section 6
with respect to the preparation and filing of Tax Returns, including providing
information required to be provided in Section 6.

        3.2.    Pre-Distribution Period and Straddle Period Tax Returns. All Tax
Returns required to be filed for Pre-Distribution Periods or Straddle Periods,
shall be:

                (1)     prepared and filed by ICN, in the case of any
Consolidated Income Tax Return; and

                (2)     in all other cases, prepared and filed, or caused to be
prepared and filed, by the Company to which such Tax Return relates.

        Ribapharm shall, for each Tax Period or portion thereof for which
Ribapharm or a member of the Ribapharm Group is included in a Tax Return
described in clause (1) of the preceding sentence, provide ICN with (i) a true
and correct pro forma tax return for the Ribapharm Group together with an
accompanying computation of Tax liability of the Group prepared in accordance
with the Stand Alone Method, (ii) separate pro forma tax returns for each member
of the Ribapharm Group together with accompanying computations of the separate
tax return Tax liabilities of each member of the Group, and (iii) a
reconciliation of book income to federal taxable income for each member of the
Ribapharm Group. Ribapharm hereby agrees to use its best efforts to provide ICN
with such returns and computations no later than the first day of the sixth
month following the end of the period to which such returns and computations
relate, but in any event shall provide such returns and computations to ICN no
later than the fifteenth day of the

                                       13

<PAGE>

sixth month following the end of the period to which such returns and
computations relate. Ribapharm, in preparing the above mentioned pro forma tax
returns for its Group, shall not consider or give effect to any (i) net
operating loss carryover or carryback, (ii) capital loss carryover or carryback,
(iii) excess charitable deduction carryover, (iv) excess tax carryover or
carryback, or (v) other similar carryback or carryback item.

        3.3.    Post-Distribution Period Tax Returns.

                (1)     All Tax Returns related exclusively to Ribapharm or to a
member of the Ribapharm Group for Post-Distribution Periods shall be prepared
and filed (or caused to be prepared and filed) by Ribapharm,

                (2)     All Tax Returns related exclusively to ICN or to a
member of the ICN Group, excluding for this purpose Ribapharm or members of the
Ribapharm Group, for Post-Distribution Periods shall be prepared and filed (or
caused to be prepared and filed) by ICN.

        3.4.    Tax Accounting Practices.

                (a)     General Rule. Except as otherwise provided in this
Section 3.4, any Tax Return for any Pre-Distribution Period or any Straddle
Period, and any Tax Return for any Post-Distribution Period to the extent items
reported on such Tax Return might reasonably affect items reported on any Tax
Return for any Pre-Distribution Period or any Straddle Period, shall be prepared
in accordance with past Tax accounting practices used with respect to the Tax
Returns in question (unless such past practices are no longer permissible under
the Code or other applicable Tax Law), and to the extent any items are not
covered by past practices (or in the event such past practices are not longer
permissible under the Code or other applicable Tax Law), in accordance with
reasonable Tax accounting practice selected by the Responsible Company.

                (b)     Reporting of Transaction Tax Items. The tax treatment
reported on any Tax Return of Tax Items relating to the Transaction shall be
consistent with the treatment of such item in the IRS Private Letter Ruling (if
issued) or the Tax Opinion (if obtained). To the extent

                                       14

<PAGE>

there is a Tax Item relating to the Transactions which is not covered by the IRS
Private Letter Ruling or the Tax Opinion, the tax treatment of such Tax Items on
a Tax Return shall be determined by the Responsible Company with respect to such
Tax Return, provided (i) there is substantial authority for such tax treatment,
and (ii) such tax treatment is not inconsistent with the tax treatment
contemplated in the IRS Private Letter Ruling or the Tax Opinion. Such Tax
Return shall be submitted for review pursuant to Section 3.5(a), and any dispute
regarding such proper tax treatment shall be referred for resolution pursuant to
Section 13 sufficiently in advance of the filing date of such Tax Return
(including extensions) to permit timely filing of the return.

        3.5.    Right to Review Tax Returns.

                (a)     General. The Responsible Company with respect to any Tax
Return shall make such Tax Return and related Tax Records available for review
by the other Company, if requested, to the extent (i) such Tax Return relates to
Taxes for which the requesting party may be liable, (ii) such Tax Return relates
to any additional Taxes for which the requesting party may be liable in whole or
in part as a result of adjustments to the amount of Taxes reported on such Tax
Return, (iii) such Tax Return relates to Taxes for which the requesting party
may have a claim for Tax Benefits under this Agreement, or (iv) the requesting
party reasonably determines that it must inspect such Tax Return to confirm
compliance with the terms of this Agreement. The Responsible Company shall use
its reasonable best efforts to make such Tax Return and Tax Records available
for review as required under this paragraph sufficiently in advance of the due
date for filing such Tax Returns to provide the requesting party with a
meaningful opportunity to analyze and comment on such Tax Returns and have such
Tax Returns modified before filing, taking into account the person responsible
for payment of the Tax (if any) reported on such Tax Return and the materiality
of the amount of Tax liability with respect to such Tax Return. The Companies
shall attempt in good faith to resolve any issues arising out of the review of
such Tax Returns or Tax Records.

                                       15

<PAGE>

                (b)     Execution of Returns Prepared by Other Party. In the
case of any Tax Return which is required to be prepared and filed by one Company
under this Agreement and which is required by law to be signed by another
Company (or by its authorized representative), the Company that is legally
required to sign such Tax Return shall not be required to sign such Tax Return
under this Agreement if there is not substantial authority for the tax treatment
of any material items reported on the Tax Return. Any such Tax Return shall be
supplied by the Company responsible for its preparation and filing to the
Company responsible for its signing at least five days prior to the due date of
such Tax Return (including applicable extensions) and such signing Company shall
deliver an executed copy of such Tax Return to the filing Company at least two
days prior to the due date of such Tax Return (including applicable extensions).

SECTION 4.      Refunds, Carrybacks and Tax Benefits.

        4.1.    Compensation for Use of Ribapharm Consolidated Period Tax Items.
In the event that (i) the ICN Group realizes an actual Tax Benefit during any
Consolidated Period as a result of the use by members of the ICN Group (other
than members of the Ribapharm Group) of Tax Items of the Ribapharm Group and
(ii) as a result of such use the Federal Income Tax liability of the Ribapharm
Group for any Post-Distribution Period is greater than the amount of such
liability computed under the Stand Alone Method (but without regard to clauses
(iii) and (iv) of Section 2.6(a)), then ICN will pay to Ribapharm, in accordance
with Section 5.7, an amount equal to the lesser of (x) the excess of the Tax
Benefit actually realized by ICN referred to in clause (i) over the amount of
any prior payments to Ribapharm pursuant to this Section 4.1 in respect of that
Tax Benefit and (y) the excess referred to in clause (ii) for such
Post-Distribution Period.

        4.2.    Claims for Refund, Carrybacks, and Self-Audit Adjustments (
"Adjustment Requests ").

                                       16

<PAGE>

                (a)     Consent Required for Adjustment Requests Related to
Consolidated or Combined Income Tax Returns. Except as provided in paragraph (b)
below, each of the Companies hereby agrees that, unless the other Company
consents in writing, which consent shall not be unreasonably delayed or
withheld, no Adjustment Request shall be filed with respect to any Consolidated
or Combined Income Tax Return that included the Ribapharm Group for a
Pre-Distribution Period and affects the Ribapharm Group Tax liability. Any
Adjustment Request which the Companies consent to make under this Section 4.2
shall be prepared and filed by the Responsible Company under Sections 3.2 and
3.3 for the Tax Return to be adjusted. The Company requesting the Adjustment
Request, if other than the Responsible Company, shall provide to the Responsible
Company all information required for the preparation and filing of such
Adjustment Request in such form and detail as reasonably requested by the
Responsible Company.

                (b)     Exception for Adjustment Requests Related to Audit
Adjustments. Each Company shall be entitled, without the consent of the other
Company, to require ICN to file an Adjustment Request to take into account any
net operating loss, net capital loss, deduction, credit, or other adjustment
attributable to such Company or any member of its Group corresponding to any
adjustment resulting from any audit by the Internal Revenue Service or other Tax
Authority with respect to Consolidated or Combined Income Tax Returns for any
Pre-Distribution Period.

                (c)     Other Adjustment Requests Permitted. Nothing in this
Section 4.2 shall prevent any Company or its Affiliates from filing any
Adjustment Request with respect to Tax Returns which are not Consolidated or
Combined Income Tax Returns or with respect to any Other Taxes; provided,
however, that neither Company shall file an amended Tax Return with respect to
Separate Company or Other Taxes for which the other Company is liable under this
Agreement without the written consent of such other Company (which consent shall
not be

                                       17

<PAGE>

unreasonably withheld). If any refund or credit is obtained as a result of any
such Adjustment Request (or otherwise), the parties shall recalculate the
amounts that would have been paid under this Agreement based on the changes
resulting in such refund or credit, and shall make such payments between them as
necessary to place each in the position it would have been in had the payments
made under this Agreement originally been made based on such changes.

                (d)     Payment of Refunds and other Tax Benefits. Except as set
forth in Section 4.2(e), any refunds or other Tax Benefits received by either
Company (or any of its Affiliates) as a result of any Adjustment Request which
are for the account of the other Company (or member of such other Company's
Group) shall be paid by the Company receiving (or whose Affiliate received) such
refund or Tax Benefit to such other Company in accordance with Section 5.

                (e)     Ordering of and Payment for Carrybacks.

                (i)     In the event that a member of the ICN Group other than a
member of the Ribapharm Group, on the one hand, and a member of the Ribapharm
Group, on the other hand, are each entitled to carryback a Tax Item to a
Pre-Distribution Period, the respective Tax Items shall be used under the rules
of applicable Tax Law (which shall be, in the case of Carrybacks to such Tax
Periods of the affiliated group of which ICN is the common parent, the rules
contained in Treasury Regulation Section 1.1502-21).

                (ii)    Any Tax refund or other Tax Benefit resulting from the
Carryback of any member of one Group (the "Carryback Group") of any Tax Item
arising after the Distribution Date to a Pre-Distribution Period shall be for
the account of the Carryback Group (and in the event the Ribapharm Group is the
Carryback Group, then upon receipt of the Tax refund or other Tax Benefit, ICN
shall pay to Ribapharm the amount of such Tax refund or other Tax Benefit);
provided, however, that if at the time of the use of the Carryback Items of a
member of the Carryback Group, a member of the other Group (the "Other Group")
possesses Carryback Tax Items which, but for the ordering rule set forth in (i)
above, would have been

                                       18

<PAGE>

available to be used (the "Other Group Carryback") in lieu of the Carryback
Group's Tax Items, then (but only to the extent of the Other Group Carryback)
the Carryback Group shall not be entitled to payment of the amount of such Tax
refund or Tax Benefit until the earlier of (X) the date on which a member of the
Other Group claims the Other Group Carryback on a Tax Return or (Y) the date on
which a member of the Carryback Group would have been able to use the Carryback
had it not been claimed with respect to the Pre-Distribution Period Tax Return.

                (iii)   In the event the Carryback of Tax Items of a member of
the ICN Group other than a member of the Ribapharm Group, or a member of the
Ribapharm Group, as the case may be, does not result in a Tax refund, due to an
offsetting Tax adjustment to a member of the Other Group, then the Other Group
shall promptly pay the amount of any decrease in Tax liability resulting from
the Carryback claim, provided, however, that in the event the Other Group
possesses Carryback Items which, but for the ordering rules set forth in (i)
above would have been available to be used in lieu of the Carryback Group's
Items, then (but only to the extent of the Other Group Carryback), the Other
Group shall not be required to pay the amount of such decrease in Tax liability
to the Carryback Group until the earlier of (X) the date on which a member of
the Other Group claims the Other Group Carryback on a Tax Return or (Y) the date
on which a member of the Carryback Group would have been able to utilize the
Carryback had it not been claimed with respect to the Pre-Distribution Period
Tax Return.

        4.3.    Adjustment of Tax Items. In the event that the Carryback of Tax
Items of one Group, or a Tax adjustment attributable to such Group under the
terms of this Agreement, results in the disallowance or limitation of Tax Items
claimed on the Tax Return as filed, the Carryback Group shall be responsible for
any increase in Tax liability resulting from the disallowance or limitation of
Tax attributes; provided, however, that in the event the disallowance or
limitation of Tax attributes results in a Tax Benefit resulting from the use of
such Tax attributes in another Tax

                                       19

<PAGE>

Period, such Tax Benefit shall be deemed to be for the account of the Carryback
Group for such purposes of this Agreement.

        4.4.    Adjustments on Audit. If, upon examination by any Tax Authority
of any Tax Return including a member of the ICN Group or Ribapharm Group for any
Tax Period, any item of deduction, credit or expense is disallowed for which ICN
is or may be liable for Taxes hereunder (or an item of income is required to be
recognized on a Tax Return which was not reported on such Tax Return), in either
such case resulting in a tax detriment suffered by the ICN Group, and such
disallowance (or recognition) results in a Tax Benefit to the Ribapharm Group
(with respect to that Tax Period or another Tax Period), then Ribapharm shall
pay to ICN the amount of such Tax Benefit that is realized in the form of an
actual reduction in Tax (which shall be computed by comparing the Tax which
would have been owed by Ribapharm but for the item giving rise to the Tax
Benefit with the Tax owed by Ribapharm taking such item into account) provided,
however, that in no case will the amount that Ribapharm is required to pay to
ICN with respect to such Tax Benefit exceed the corresponding tax detriment to
ICN (reduced by payments previously made by Ribapharm to ICN with respect to
such Tax Benefit). Any payment required to be made hereunder shall be made in
accordance with Section 5.10. The provisions of this Section 4.4 shall apply
mutatis mutandis where an item of deduction, credit or expense is disallowed for
which Ribapharm is or may be liable for Taxes hereunder (or any item of income
is required to be recognized on a Tax Return which was not reported on such Tax
Return), as they apply where the ICN Group suffers such a detriment. For
avoidance of doubt, any payment required to be made by ICN to the Ribapharm
Group under this Section 4.4 shall, to the extent applicable, be deemed as an
offset to amounts owing by Ribapharm to ICN under Section 2.2 hereof.

                                       20

<PAGE>

SECTION 5.      Tax Payments and Intercompany Billings.

        5.1.    Payment of Taxes With Respect to ICN Federal Consolidated
Returns. In the case of any ICN Federal Consolidated Return-

                (a)     Computation and Payment of Tax Due. Unless otherwise
agreed to by the Companies, at least five business days prior to any Payment
Date, ICN shall compute the amount of Tax required to be paid to the Internal
Revenue Service (taking into account the requirements of Section 3.4 relating to
consistent accounting practices) with respect to such Tax Return on such Payment
Date and shall notify Ribapharm in writing of the amount of Tax required to be
paid on such Payment Date. ICN will pay such amount to the Internal Revenue
Service on or before such Payment Date.

                (b)     Computation and Payment of Ribapharm Liability With
Respect to Tax Due. Within 30 days following any Payment Date, Ribapharm will
pay to ICN the excess (if any) of

                        (i)     the amount of liability determined as of such
Payment Date with respect to the applicable Tax Period allocable to Ribapharm in
a manner consistent with the provisions of Section 2.2, over

                        (ii)    the amount equal to the cumulative net payments
with respect to such Tax Return prior to such Payment Date made by Ribapharm or
members of its Group.  If the amount in clause (ii) above is greater than the
amount in clause (i) above as of any Payment Date, then ICN shall pay such
excess to Ribapharm within 30 days following the Payment Date.

                (c)     Interest on Intergroup Tax Allocation Payments. In the
case of any payments to ICN required under paragraph (b) of this Section 5.1,
Ribapharm shall also pay to ICN an amount of interest computed at the Prime Rate
on the amount of the payment required based on the number of days from the
applicable Payment Date until the date of Ribapharm's subsequent payment. In the
case of any payments by ICN required under paragraph (b) of this Section 5.1,
ICN shall also pay to Ribapharm an amount of interest computed at the Prime Rate

                                       21

<PAGE>

on the amount of the payment required based on the number of days from the
applicable Payment Date until the date of ICN's subsequent payment of such
amount to Ribapharm.

        5.2.    Payment of Federal Income Tax Related to Adjustments.

                (a)     Adjustments Resulting in Underpayments. ICN shall pay to
the Internal Revenue Service when due any additional Federal Income Tax required
to be paid as a result of any adjustment to the tax liability with respect to
any ICN Federal Consolidated Return. Ribapharm shall pay to ICN an amount that
is allocable to Ribapharm under Section 2.2 within 30 days from the later of (i)
the date the additional Tax was paid by ICN or (ii) the date of receipt by
Ribapharm of a written notice and demand from ICN for payment of the amount due,
accompanied by evidence of payment and a statement detailing the Taxes paid and
describing in reasonable detail the particulars relating thereto. Any payments
required under this Section 5.2 (a) shall include interest computed at the Prime
Rate based on the number of days from the date the additional Tax was paid by
ICN to the date of the payment under this Section 5.2(a).

                (b)     Adjustments Resulting in Overpayments. Within 30 days of
receipt by ICN of any Tax Benefit resulting from any adjustment to the tax
liability with respect to any ICN Federal Consolidated Return, ICN shall pay to
Ribapharm its share of any such Tax Benefit, as determined in accordance with
the principles of Sections 2.2 and 4. Any payments required under this Section
5.2(b) shall include interest computed at the Prime Rate based on the number of
days from the date the Tax Benefit was received by ICN to the date of payment to
Ribapharm under this Section 5.2(b).

        5.3.    Payment of State Income Tax Relating to Pre-Distribution
Periods.

                (a)     Computation and Payment of Tax Due. Unless otherwise
agreed to by the Companies, at least five business days prior to any Payment
Date for any Tax Return with respect to any State Income Tax relating to a
Pre-Distribution Period, the Responsible Company shall compute the amount of Tax
required to be paid to the applicable Tax Authority (taking into

                                       22

<PAGE>

account the requirements of Section 3.4 relating to consistent accounting
practices) with respect to such Tax Return on such Payment Date and--

                        (i)     If such Tax Return is a state Consolidated or
Combined Income Tax Return, the Responsible Company shall, if ICN is not the
Responsible Company with respect to such Tax Return, notify ICN in writing of
the amount of Tax required to be paid on such Payment Date. ICN will pay such
amount to such Tax Authority on or before such Payment Date.

                        (ii)    If such Tax Return is with respect to a Separate
Company Tax, the Responsible Company shall, if it is not the Company liable for
the Tax reported on such Tax Return, notify the Company liable for such Tax in
writing of the amount of Tax required to be paid on such Payment Date. The
Company liable for such Tax will pay such amount to such Tax Authority on or
before such Payment Date.

                (b)     Computation and Payment of Ribapharm Liability With
Respect to Tax Due. Within 30 days following the due date (including extensions)
for filing any Consolidated or Combined Income Tax Return with respect to State
Income Taxes (excluding any Tax Return with respect to payment of estimated
Taxes or Taxes due with a request for extension of time to file) relating to a
Pre-Distribution Period, Ribapharm shall pay to ICN the Tax liability allocable
to Ribapharm as determined by ICN under the provisions of Sections 2.3 and 4
(and following the procedures described in Section 5.2(a)), plus interest
computed at the Prime Rate on the amount of the payment based on the number of
days from the due date (including extensions) to the date of payment by
Ribapharm to ICN.

        5.4.    Payment of State Income Taxes Related to Adjustments.

                (a)     Adjustments Resulting in Underpayments. ICN shall pay to
the applicable Tax Authority when due any additional State Income Tax required
to be paid as a result of any adjustment to the Tax liability with respect to
any Tax Return for any state Consolidated or

                                       23

<PAGE>

Combined Income Tax Return with respect to State Income Taxes for any
Pre-Distribution Period. Ribapharm shall pay to ICN its respective share of any
such additional Tax payment determined in accordance with Sections 2.3 and 4
within 30 days from the later of (i) the date the additional Tax was paid by ICN
or (ii) the date of receipt by Ribapharm of a written notice and demand from ICN
for payment of the amount due, accompanied by evidence of payment and a
statement detailing the Taxes paid and describing in reasonable detail the
particulars relating thereto. Ribapharm shall also pay to ICN interest on its
respective share of such Tax computed at the Prime Rate based on the number of
days from the date the additional Tax was paid by ICN to the date of its payment
to ICN under this Section 5.4(a).

                (b)     Adjustments Resulting in Overpayments. Within 30 days of
receipt by ICN of any Tax Benefit resulting from any adjustment to the Tax
liability with respect to any Consolidated or Combined Tax Return with respect
to State Income Taxes for any Pre-Distribution Period, ICN shall pay to
Ribapharm its share of any such Tax Benefit determined in accordance with the
principles of Sections 2.3 and 4. Any payments required under this Section
5.4(b) shall include interest computed at the Prime Rate based on the number of
days from the date the Tax Benefit was received by ICN to the date of payment
under this Section 5.4(b).

        5.5.    Payment of Separate Company Taxes and Other Taxes. Each Company
shall pay, or shall cause to be paid, to the applicable Tax Authority when due
all Separate Company Taxes and Other Taxes owed by such Company or a member of
such Company's Group.

        5.6.    Indemnification Payments. If any Company (the "payor") is
required to pay to a Tax Authority a Tax that another Company (the "responsible
party") is required to pay to such Taxing Authority under this Agreement, the
responsible party shall reimburse the payor within 30 days of delivery by the
payor to the responsible party of an invoice for the amount due, accompanied by
evidence of payment and a statement detailing the Taxes paid and describing in
reasonable detail the particulars relating thereto. The reimbursement shall
include interest on the

                                       24

<PAGE>

Tax payment computed at the Prime Rate based on the number of days from the date
of the payment to the Tax Authority to the date of reimbursement under this
Section 5.6.

        5.7.    Compensation for use of Ribapharm Consolidated Period Tax Items.
In the event ICN is required to pay Ribapharm in accordance with Section 4.1,
Ribapharm shall deliver to ICN an invoice stating the amount due to Ribapharm,
accompanied by a reasonably detailed calculation of that amount, as prescribed
by section 4.1. ICN shall pay Ribapharm within 30 days from the due date
(including any extensions) for the Tax Return filed by Ribapharm with respect to
such amount, including interest computed at the Prime Rate based on the number
of days from such due date to the date ICN pays Ribapharm.

        5.8.    Payment of Refunds and Other Tax Benefits.

                (a)     Except as otherwise provided in this Agreement, if a
member of one Group receives a Tax refund or other Tax Benefit with respect to
Taxes for which a member of the other Group is liable hereunder, the Company
receiving such Tax refund or other Tax Benefit shall make a payment to the
Company who is liable for such Taxes hereunder within 30 days following the
receipt of the Tax refund or other Tax Benefit in an amount equal to such Tax
refund or other Tax Benefit, plus interest on such amount computed at the Prime
Rate based on the number of days from the date of receipt of the Tax refund or
other Tax Benefit to the date of payment under this Section 5.8.

                (b)     In the event one Group is reimbursed for its payment of
a Tax liability of the other Group, the amount of such reimbursement shall be
computed net of any Tax Benefit realized by the reimbursed Group as the result
of payment of the other Group's Tax liability.

        5.9.    Payment for Carrybacks. Each Company shall pay the other Company
for Carrybacks in accordance with Section 4.2(e). Any such payment shall include
interest at the Prime Rate based on the number of days from the date Company is
required to make the payment under Section 4.2(e) to the date the Company
actually makes the payment.

                                       25

<PAGE>

        5.10.   Payment for Adjustments on Audit. Any payment required under
Section 4.4 shall be made within 30 days of the due date (including any
extensions) of the Tax Return on which the Tax Benefit described in that section
is claimed. Such payment shall include interest computed at the Prime Rate based
on the number of days from such due date to the date the payment is made.

SECTION 6.      Assistance and Cooperation.

        6.1.    General. Each of the Companies shall cooperate (and cause their
respective Affiliates to cooperate) with each other and with each other's
agents, including accounting firms and legal counsel, in connection with Tax
matters relating to the Companies and their Affiliates including (i) preparation
and filing of Tax Returns, (ii) determining the liability for and amount of any
Taxes due (including estimated Taxes) or the right to and amount of any refund
of Taxes, (iii) examinations of Tax Returns, and (iv) any administrative or
judicial proceeding in respect of Taxes assessed or proposed to be assessed.
Such cooperation shall include making all information and documents in their
possession relating to the other Companies and their Affiliates available to
such other Companies as provided in Section 7. Each of the Companies shall also
make available to each other, as reasonably requested and available, personnel
(including officers, directors, employees and agents of the Companies or their
respective Affiliates) responsible for preparing, maintaining, and interpreting
information and documents relevant to Taxes, and personnel reasonably required
as witnesses or for purposes of providing information or documents in connection
with any administrative or judicial proceedings relating to Taxes. Any
information or documents provided under this Section 6 shall be kept
confidential by the Company receiving the information or documents, except as
may otherwise be necessary in connection with the filing of Tax Returns or in
connection with any administrative or judicial proceedings relating to Taxes.

        6.2.    Income Tax Return Information. Each Company will provide to each
other Company information and documents relating to their respective Groups
required by the other

                                       26

<PAGE>

Companies to prepare Tax Returns. The Responsible Company shall determine a
reasonable compliance schedule for such purpose in accordance with past
practices. Any additional information or documents the Responsible Company
requires to prepare such Tax Returns will be provided in accordance with past
practices, if any, or as the Responsible Company reasonably requests and in
sufficient time for the Responsible Company to file such Tax Returns timely.

SECTION 7.      Tax Records.

        7.1.    Retention of Tax Records. Except as provided in Section 7.2,
each Company shall preserve and keep all Tax Records exclusively relating to the
assets and activities of their respective Groups for Pre-Distribution Periods,
and ICN shall preserve and keep all other Tax Records relating to Taxes of the
Groups for Pre-Distribution Periods, for so long as the contents thereof may
become material in the administration of any matter under the Code or other
applicable Tax Law, but in any event until the later of (i) the expiration of
any applicable statutes of limitation, as extended, and (ii) seven years after
the Distribution Date. Prior to disposing of any Tax Records which it is
required to preserve and keep under this Section 7, a Company shall provide
90-days written notice to the other Company. Such notice shall include a list of
the records to be disposed of describing in reasonable detail each file, book,
or other record accumulation being disposed of. The notified Company shall have
the opportunity, at its cost and expense, to copy or remove, within such 90-day
period, all or any part of such Tax Records.

        7.2.    State Income Tax Returns. Tax Returns with respect to State
Income Taxes and workpapers prepared in connection with preparing such Tax
Returns shall be preserved and kept, and disposed of, in accordance with the
guidelines of Section 7.1, by the Company responsible for preparing and filing
the applicable Tax Return.

        7.3.    Access to Tax Records. The Companies and their respective
Affiliates shall make available to each other for inspection and copying during
normal business hours upon reasonable

                                       27

<PAGE>

notice all Tax Records in their possession to the extent reasonably requested by
the other Company in connection with the preparation of Tax Returns, audits,
litigation, or the resolution of items under this Agreement.

SECTION 8.      Tax Contests.

        8.1.    Notice. Each of the parties shall provide prompt notice to the
other party of any pending or threatened Tax audit, assessment or proceeding or
other Tax Contest of which it becomes aware related to Taxes for Tax Periods for
which it is indemnified by the other party hereunder. Such notice shall contain
factual information (to the extent known) describing any asserted Tax liability
in reasonable detail and shall be accompanied by copies of any notice and other
documents received from any Tax Authority in respect of any such matters. If an
indemnified party has knowledge of an asserted Tax liability with respect to a
matter for which it is to be indemnified hereunder and such party fails to give
the indemnifying party prompt notice of such asserted Tax liability, then (i) if
the indemnifying party is precluded from contesting the asserted Tax liability
in any forum as a result of the failure to give prompt notice, the indemnifying
party shall have no obligation to indemnify the indemnified party for any Taxes
arising out of such asserted Tax liability, and (ii) if the indemnifying party
is not precluded from contesting the asserted Tax liability in any forum, but
such failure to give prompt notice results in a monetary detriment to the
indemnifying party, then any amount which the indemnifying party is otherwise
required to pay the indemnified party pursuant to this Agreement shall be
reduced by the amount of such detriment.

        8.2.    Control of Tax Contests. Each Company shall have full
responsibility and discretion in handling, settling or contesting any Tax
Contest involving a Tax for which it is liable pursuant to Section 2 of this
Agreement; provided, however, ICN shall have full responsibility and discretion
in handling, settling or contesting any Tax Contest with respect to a
Consolidated or

                                       28

<PAGE>

Combined Income Tax Return of the ICN Group. Furthermore, both Companies may
participate in any Tax Contest with respect to Restructuring Taxes regardless of
whether it has liability or indemnification obligations with respect to such
Taxes under this Agreement.

SECTION 9.      No Inconsistent Actions.

                (a)     Each of the Companies covenants and agrees that it has
not and will not take any action, and it has and will cause its Affiliates to
refrain from taking any action, which may be inconsistent with the Tax treatment
of the Transactions as contemplated in the Application for Ruling, Tax Opinion
Submission (if made), IRS Private Letter Ruling (if issued) or Tax Opinion (if
obtained) (any such action is referred to in this Section 9 as a "Tainting
Act"), unless (i) the Company or Affiliate thereof proposing such Tainting Act
(the "Requesting Party") either (A) obtains a ruling with respect to the
Tainting Act from the Internal Revenue Service or other applicable Tax Authority
that is reasonably satisfactory to the other Company (the "Requested Party")
(except that the Requesting Party shall not submit any such ruling request if a
Requested Party determines in good faith that filing such request might have a
materially adverse effect upon such Requested Party), or (B) obtains an opinion
reasonably acceptable to each Requested Party of independent,
nationally-recognized tax counsel acceptable to each Requested Party, on a basis
of assumed facts and representations consistent with the facts at the time of
such action, that such Tainting Act will not affect the Tax treatment of the
Transactions as contemplated in the Application for Ruling, Tax Opinion
Submission (if made), IRS Private Letter Ruling (if issued) or Tax Opinion (if
obtained), or (ii) each Requested Party consents in writing to such Tainting
Act, which consent shall be granted or withheld in the sole and absolute
discretion of each such Requested Party. Without limiting the foregoing:

                        (i)     Specified Actions. During the four-year period
beginning two years before the Distribution Date, unless clause (i) or (ii) of
the preceding paragraph is satisfied with

                                       29

<PAGE>

respect to the applicable action, no Company or its Affiliate has or will (A)
liquidate or merge with or into any other corporation (other than a merger which
results in the outstanding stock of such Company or its Affiliates immediately
before the merger continuing to represent at least eighty (80) percent of the
outstanding voting stock and non-voting stock of the merged corporations after
the transaction); (B) excluding the Initial Public Offering, issue more than ten
(10) percent, in the aggregate, by vote or value, of its capital stock in one or
more transactions; (C) redeem, purchase or otherwise reacquire its capital stock
in one or more transactions, except to the extent such redemption, purchase or
reacquisition meets the requirements of section 4.05(1)(b) of Revenue Procedure
96-30; (D) sell, exchange, distribute or otherwise dispose of, other than in the
ordinary course of business, more than twenty-five (25) percent of the assets
constituting the trades or businesses relied upon in the Application for Ruling,
Tax Opinion Submission (if made), IRS Private Letter Ruling (if issued) or Tax
Opinion (if obtained) to satisfy Section 355(b) of the Code; or (E) discontinue
or cause to be discontinued the active conduct of the trades or businesses
relied upon in the Application for Ruling, Tax Opinion Submission (if made), IRS
Private Letter Ruling (if issued) or Tax Opinion (if obtained) to satisfy
Section 355(b) of the Code.

                        (ii)    No Inconsistent Plan or Intent. Each of the
Companies represents and warrants that neither it nor any of its Affiliates has
any plan or intent to take any action which is inconsistent with any factual
statements or representations in the Application for Ruling, and, in the event a
Tax Opinion Submission is made, each of the Companies represents and warrants
that neither it nor any of its Affiliates will form any plan or take any action
which is inconsistent with any factual statements or representations in such Tax
Opinion Submission. Regardless of any change in circumstances, each of the
Companies covenants and agrees that it will not take, and it will cause its
Affiliates to refrain from taking, any such inconsistent action on or before the
second anniversary of the Distribution Date other than as permitted in this
Section 9.

                                       30

<PAGE>

                        (iii)   355(e) Covenant. Notwithstanding anything in
this Agreement to the contrary, each of ICN and Ribapharm covenants and agrees
that, during the two-year periods ending on and beginning on the Distribution
Date, unless clause (i) or (ii) of section 9(a) of this Agreement is satisfied
with respect to the applicable action, it has not and will not enter into any
negotiations, agreements or arrangements with respect to transactions or events
(including stock issuances, option grants, capital contributions or
acquisitions) which may cause the Distribution to be treated as part of a plan
pursuant to which one or more persons acquire directly or indirectly ICN or
Ribapharm stock, as the case may be, representing a "50 percent or greater
interest" within the meaning of Section 355(e)(4) of the Code.

                        (iv)    Amended or Supplemental Rulings. Each of the
Companies covenants and agrees that it will not file, and it will cause its
Affiliates to refrain from filing, any amendment or supplement to the
Application for Ruling with respect to the Transactions subsequent to the
Distribution Date without the consent of the other Companies, which consent
shall not be unreasonably withheld.

                        (v)     Liability for Breach of Representations or
Omission or Misstatement of Material Facts. Ribapharm represents that (i) it has
read the Application for Ruling, and will read any amendment or supplement to
the Application for Ruling (each a "Supplemental Application") and any Tax
Opinion Submission made available to it by ICN, (ii) all information relating to
Ribapharm or any member of the Ribapharm Group contained in such Application for
Ruling, Supplemental Application and Tax Opinion Submission is or will be true,
correct and complete in all material respects at the time such information is
submitted, and (iii) except to the extent that Ribapharm shall have notified ICN
in writing to the contrary, with reasonable specificity and as promptly as
possible, prior to the Distribution, all such information supplied to ICN in
writing by Ribapharm or any member of the Ribapharm Group will be true, correct
and complete in all material respects as of the Distribution Date. If the IRS
withdraws all,

                                       31

<PAGE>

or any portion, of an IRS Private Letter Ruling issued to ICN in connection with
the Distribution, or if any Tax Opinion obtained by ICN is rendered inapplicable
or ineffective because of a breach by Ribapharm or any member of the Ribapharm
Group of a representation or because of the omission or misstatement by
Ribapharm or any member of the Ribapharm Group of any material fact, which
breach, omission or misstatement was not known to ICN on or before the
Distribution Date, Ribapharm and every member of the Ribapharm Group shall be
responsible for one hundred (100) percent of any Restructuring Tax resulting
from such breach, omission or misstatement, and shall jointly and severally
indemnify, on an after-tax-basis, ICN, each member of the ICN Group other than a
member of the Ribapharm Group, and their directors, officers and employees and
hold them harmless from and against such Restructuring Tax.

                (b)     Notwithstanding anything to the contrary in this
Agreement, each Company shall be solely liable for, and shall indemnify and hold
harmless the other Company from any Restructuring Tax resulting from a Tainting
Act by such first Company or its Affiliates, regardless of whether clause (i) or
(ii) of Section 9(a) was satisfied with respect to such Tainting Act.

                                       32

<PAGE>

SECTION 10.     Survival of Obligations.

        The representations, warranties, covenants and agreements set forth in
this Agreement shall be unconditional and absolute and shall remain in effect
without limitation as to time.

SECTION 11.     Employee Matters.

        Each of the Companies agrees to utilize, or cause its Affiliates to
utilize, the alternative procedure set forth in section 5 of Revenue Procedure
96-60, 1996-2 C.B. 399, with respect to wage reporting.

SECTION 12.     Treatment of Payments; Tax Gross Up.

        12.1.   Treatment of Tax Indemnity and Tax Benefit Payments. In the
absence of any change in tax treatment under the Code or other applicable Tax
Law, any Tax indemnity payments or Tax Benefit payments made by a Company under
Section 5 shall be reported for Tax purposes by the payor and the recipient as
distributions or capital contributions, as appropriate, occurring immediately
before the Distribution on the Distribution Date, but only to the extent the
payment does not relate to a Tax allocated to the payor in accordance with
Treasury Regulation Section 1.1502-33(d) (or under corresponding principles of
other applicable Tax Laws).

        12.2.   Tax Gross Up. If notwithstanding the manner in which Tax
indemnity payments and Tax Benefit payments were reported, there is an
adjustment to the Tax liability of a Company as a result of its receipt of a
payment pursuant to this Agreement, such payment shall be appropriately adjusted
so that the amount of such payment, reduced by the amount of all Income Taxes
payable with respect to the receipt thereof (but taking into account all
correlative Tax Benefits resulting from the payment of such Income Taxes), shall
equal the amount of the payment which the Company receiving such payment would
otherwise be entitled to receive pursuant to this Agreement.

                                       33

<PAGE>

        12.3.   Interest Under This Agreement. Anything herein to the contrary
notwithstanding, to the extent one Company ("indemnitor") makes a payment of
interest to another Company ("indemnitee") under this Agreement with respect to
the period from the date that the indemnitee made a payment of Tax to a Tax
Authority to the date that the indemnitor reimbursed the indemnitee for such Tax
payment, or with respect to the period from the date that the indemnitor
received a Tax Benefit to the date indemnitor paid the indemnitee with respect
to such Tax Benefit, the interest payment shall be treated as interest expense
to the indemnitor (deductible to the extent provided by law) and as interest
income by the indemnitee (includible in income to the extent provided by law).
The amount of the payment shall not be adjusted under Section 12.2 to take into
account any associated Tax Benefit to the indemnitor or increase in Tax to the
indemnitee.

SECTION 13.     Disagreements.

        If after good faith negotiations the parties cannot agree on the
application of this Agreement to any matter concerning (i) calculation or
allocation of any liability for Tax, (ii) computation or payment of any Tax due,
(iii) compensation for any Tax Benefit, (iv) preparation or filing of any Tax
Return or (v) control of any Tax Contest, then the matter will be referred to an
independent law firm or an accounting firm acceptable to each of the parties
(the "Firm"). The Firm shall furnish written notice to the parties of its
resolution of any such disagreement as soon as practical, but in any event no
later than 45 days after its acceptance of the matter for resolution. Any such
resolution by the Firm will be conclusive and binding on all parties to this
Agreement. In accordance with Section 15, each party shall pay its own fees and
expenses (including the fees and expenses of its representatives) incurred in
connection with the referral of the matter to the Firm. All fees and expenses of
the Firm in connection with such referral shall be shared equally by the parties
affected by the matter.

                                       34

<PAGE>

SECTION 14.     Late Payments.

        Any amount owed by one party to another party under this Agreement which
is not paid when due shall bear interest at the Prime Rate plus two percent,
compounded on each March 31, June 30, September 30 and December 31, from the due
date of the payment to the date paid. To the extent interest required to be paid
under this Section 14 duplicates interest required to be paid under any other
provision of this Agreement, interest shall be computed at the higher of the
interest rate provided under this Section 14 or the interest rate provided under
such other provision.

SECTION 15.     Expenses.

        Except as provided in Section 14, each Company and its Affiliates shall
bear their own expenses incurred in connection with preparation of Tax Returns,
Tax Contests, and other matters related to Taxes under the provisions of this
Agreement.

SECTION 16.     General Provisions.

        16.1.   Notices. All notices and other communications hereunder shall be
in writing and shall be delivered in person, by telecopy, by express or
overnight mail delivered by a nationally recognized air courier (delivery
charges prepaid), or by registered or certified mail (postage prepaid, return
receipt requested) to the respective parties as follows:

                (a)     If to ICN, to:

                        ICN Pharmaceuticals, Inc.
                        3300 Hyland Avenue
                        Costa Mesa, CA  92626
                        Attention:  Gregory Keever, Esq.

                                       35

<PAGE>

                (b)     If to Ribapharm, to:

                        Ribapharm Inc.
                        3300 Hyland Avenue
                        Costa Mesa, CA  92626
                        Attention:  Roger D. Loomis, Jr., Esq.

or to such other address as the party to whom notice is given may have
previously furnished to the others in writing in the manner set forth above. Any
notice or communication delivered in person shall be deemed effective on
delivery or when delivery is refused. Any notice or communication sent by
telecopy or by air courier shall be deemed effective on the first Business Day
at the place at which such notice or communication is received following the day
on which such notice or communication was sent.

        16.2.   Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same agreement. The Agreement may be
delivered by facsimile transmission of a signed copy thereof.

        16.3.   Binding Effect; Assignment. This Agreement and all of the
provisions hereof shall be binding upon the parties hereto and inure to the
benefit of the parties hereto and their respective successors and permitted
assigns. Except with respect to a merger of either party, neither this Agreement
nor any of the rights, interests or obligations hereunder shall be assigned by
either party hereto without the prior written consent of the other party, which
consent shall not be unreasonably withheld or delayed; provided, however, that
ICN and Ribapharm may assign their respective rights, interests, duties,
liabilities and obligations under this Agreement to any of

                                       36

<PAGE>

their respective subsidiaries, but such assignment shall not relieve ICN or
Ribapharm, as the assignee, of its obligations hereunder. The schedules attached
hereto or referred to herein are an integral part of this Agreement and are
hereby incorporated into this Agreement and made a part hereof as if set forth
in full herein.

        16.4.   Dispute Resolution. Except as otherwise provided for in Section
13, resolution of any and all disputes arising from or in connection with this
Agreement, whether based on contract, tort, or otherwise (collectively,
"Disputes"), shall be governed by and settled in accordance with the provisions
of this Section 16.4. The parties hereto shall use all commercially reasonable
efforts to settle all Disputes without resorting to mediation, arbitration,
litigation or other third party dispute resolution mechanisms. If any Dispute
remains unsettled, the parties hereby agree to mediate such Dispute using a
mediator reasonably acceptable to all parties involved in such Dispute. If the
parties are unable to resolve such dispute through mediation, each party will be
free to commence proceedings for the resolution thereof. No party shall be
entitled to consequential, special, exemplary or punitive damages.

        16.5.   Severability. Any provision of this Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof. Any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.

        16.6.   Waiver. The observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or
prospectively) by the party entitled

                                       37

<PAGE>

to enforce such term, but such waiver shall be effective only if it is in
writing signed by the party against which such waiver is to be asserted. Unless
otherwise expressly provided in this Agreement, no delay or omission on the part
of any party in exercising any right or privilege under this Agreement shall
operate as a waiver thereof, nor shall any waiver on the part of any party of
any right or privilege under this Agreement operate as a waiver of any other
right or privilege under this Agreement nor shall any single or partial exercise
of any right or privilege preclude any other or further exercise thereof or the
exercise of any other right or privilege under this Agreement. No failure by
either party to take any action or assert any right or privilege hereunder shall
be deemed to be a waiver of such right or privilege in the event of the
continuation or repetition of the circumstances giving rise to such right unless
expressly waived in writing by the party against whom the existence of such
waiver is asserted.

        16.7.   Amendment. This Agreement may not be amended or modified in any
respect except by a written agreement signed by both of the parties hereto.

        16.8.   Authority. Each of the parties hereto represents to the other
that (a) it has the corporate power and authority to execute, deliver and
perform this Agreement, (b) the execution, delivery and performance of this
Agreement by it has been duly authorized by all necessary corporate action, (c)
it has duly and validly executed and delivered this Agreement, and (d) this
Agreement is a legal, valid and binding obligation, enforceable against it in
accordance with its terms subject to applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting creditors' rights
generally and general equity principles.

                                       38

<PAGE>

        16.9.   Interpretation. The headings contained in this Agreement, in any
Schedule hereto and in the table or contents to this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. Any capitalized term used in any Schedule but not otherwise
defined therein, shall have the meaning assigned to such term in this Agreement.
When a reference is made in this Agreement to an Article or a Section or
Schedule, such reference shall be to an Article or Section of, or a Schedule to,
this Agreement unless otherwise indicated.

        16.10.  Effective Time. This Agreement shall become effective upon the
time of purchase of the Firm Shares, as defined in the Underwriting Agreement by
and among ICN, Ribapharm and the underwriters named therein relating to the
Initial Public Offering.

                                       39

<PAGE>

        IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by the respective officers as of the date set forth above.

                                              ICN PHARMACEUTICALS, INC.

                                              By:
                                                  --------------------------
                                              Name:
                                              Title:

                                              RIBAPHARM INC.

                                              By:
                                                  --------------------------
                                              Name:
                                              Title:

                                       40

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]